Article Text

PDF
CASE REPORT
Terminal deoxynucleotidyl transferase (TdT)-negative T-cell lymphoblastic lymphoma with loss of the T-cell lineage-specific marker CD3 at relapse: a rare entity with an aggressive outcome
  1. Masroor Hassan1,
  2. Hafez Mohammad Ammar Abdullah2,
  3. Abdul Wahid3,
  4. Muhammad Ashraf Qamar1
  1. 1 Department of Pathology, Rehman Medical Institute, Peshawar, Pakistan
  2. 2 Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, South Dakota, USA
  3. 3 Department of Oncology, Rehman Medical Institute, Peshawar, Pakistan
  1. Correspondence to Dr Hafez Mohammad Ammar Abdullah, ammar.abdullah{at}usd.edu

Summary

Terminal deoxynucleotidyl transferase (TdT)-negative T-cell lymphoblastic lymphoma is a variant of T-cell lymphoblastic lymphoma/T-cell lymphoblastic leukaemia. TdT is a marker of immaturity expressed in 90%–95% cases of lymphoblastic lymphoma and useful in differentiating it from other mature lymphomas/leukaemias. It has been associated with poorer response to chemotherapy and a more aggressive outcome. Here we present a case of TdT-negative T-cell lymphoblastic lymphoma in a 28-year-old man who presented with superior vena cava syndrome. The patient was treated with hyper-cyclophosphamide,vincristine, Adriamycin, dexamethasone (CVAD), however unfortunately suffered a relapse 1 year later. A unique feature of our case was that on relapse, the patient lost expression of the T-cell lineage-specific marker CD3, which has previously not been reported in association with TdT-negative T-cell lymphoblastic lymphoma. The patient failed to respond to chemotherapy on his relapse and died.

  • cancer intervention
  • haematology (incl blood transfusion)
  • oncology

Statistics from Altmetric.com

Footnotes

  • Contributors MH and HMAA were responsible for writing the background and discussion. AW and MAQ were responsible for writing the case presentation and summary.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.